OP2 Drugs has a total of 16 patent applications. Its first patent ever was published in 2016. It filed its patents most often in Canada, EPO (European Patent Office) and Israel. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and macromolecular chemistry and polymers are BUGWORKS RES INC, ACCENDATECH and SUMMIT THERAPEUTICS PLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Canada | 3 | |
#2 | EPO (European Patent Office) | 2 | |
#3 | Israel | 2 | |
#4 | Republic of Korea | 2 | |
#5 | United States | 2 | |
#6 | WIPO (World Intellectual Property Organization) | 2 | |
#7 | Australia | 1 | |
#8 | China | 1 | |
#9 | Mexico | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Macromolecular chemistry and polymers |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Heterocyclic compounds | |
#4 | Polysaccharides | |
#5 | Macromolecular compounds compositions |
# | Name | Total Patents |
---|---|---|
#1 | Diolez Philippe | 12 |
#2 | Petitjean Olivier | 11 |
#3 | Marin Frederic | 7 |
#4 | Detaille Dominique | 6 |
#5 | Marin Frédéric | 5 |
#6 | Audoore Natascha | 3 |
#7 | Belgsir El Mustapha | 3 |
#8 | Pineau Nicolas | 3 |
#9 | De Cock Ine | 3 |
#10 | Dereymaker Aswin | 3 |
Publication | Filing date | Title |
---|---|---|
WO2020049166A1 | Pharmaceutical composition comprising cyclodextrin compexes of anethole trithione or derivatives thereof | |
WO2018162581A1 | Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ros) production | |
CN110662535A | Demethylanisolanetrithione derivatives for the treatment of diseases associated with mitochondrial Reactive Oxygen Species (ROS) production |